Interscalene Analgesia

2

Review clinical trials related to Interscalene Analgesia. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Continuous Interscalene Blocks and Rebound Pain

The primary objectives of this present study are to examine whether a continuous interscalene block of a total duration of 48 hours reduces the incidence of rebound pain comparatively to single-shot interscalene block, through the evaluation of the NRS scores at rest and on movement in the postoperative period at 24, 48, 72 and 96 hours as well as the total opioid consumption in the same timeframe for patients undergoing total shoulder arthroplasty. Rebound pain has been defined in some studies as the "the transition from well-controlled pain (numerical rating scale \[NRS\] ≤3) while the block is working to severe pain (NRS ≥7) within 24 h of block performance."

Participants needed: 154
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: University of CalgaryUpdated: Aug 19, 2026Locations: 1
Eligibility criteria

Adults aged >18 years of age [+2]

ASA IV [+6]

Status: Recruiting

Analgesic Effect of Supraclavicular Block and Interscalene Analgesia Versus an Intercostobrachial Nerve Block Versus PCA in Forearm Surgery

The etiology of tourniquet pain is complex, and the study team hypothesizes that blocking with Interscalene brachial plexus block (ISBPB) is more efficient in decreasing the incidence of tourniquet pain in comparison with other techniques. As there is a paucity of studies that evaluate the effect of intercostobrachial nerve (ICBN) block and ISBPB and Patient-Controlled Analgesia (PCA) with a supraclavicular brachial plexus block (SCBPB) on tourniquet pain in forearm surgery, Therefore, we established this randomized study to compare ISBPB and ICBN and PCA with fentanyl with SCBPB in terms of the incidence and severity of tourniquet pain in patients undergoing forearm surgery.

Participants needed: 60
Trial details
Phase: Phase 4Age: 18-70Biological sex: AllType: InterventionalSponsor: Al-Azhar UniversityUpdated: Jan 6, 2026Locations: 1
Eligibility criteria

aged more than 18 years, [+3]

Contraindication to regional anesthesia. [+4]